The Business Group on Health podcast recently interviewed ICER’s President-Elect Sarah Emond, MPP on the US cell and gene therapy landscape. Here’s a brief excerpt from their discussion:

Sarah Emond: “I think we’re going to meet this moment…I think that the science and the magnitude of the benefit that these therapies are bringing to patients is so large that we don’t have any choice but to figure out how to do this in a way that’s sustainable.”

Most recently ICER has reviewed Casgevy and Lyfgenia for sickle cell disease. We also reviewed arsa-cel for metachromatic leukodystrophy. Click here for all ICER assessments.